Entera Bio Stock

Entera Bio Liabilities

The The Liabilities of Entera Bio (ENTX) as of Jul 25, 2026 is 2.89 M USD. In the previous year, The Liabilities was 1.31 M USD — a change of 120.76% (higher).

Liabilities

2.89 MUSD

YoY

120.76%

Last updated:

In 2026, Entera Bio's total liabilities amounted to 2.89 M USD, a 120.76% difference from the 1.31 M USD total liabilities in the previous year.

Access this data via the Eulerpool API

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Entera Bio's Liabilities

Entera Bio's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Entera Bio's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Entera Bio's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Entera Bio's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Entera Bio’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Entera Bio stock

The Liabilities of Entera Bio is 2.89 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Entera Bio

All Key Metrics — Entera Bio